تالیفات

 

High-dose intravenous steroid pulse therapy in ocular involvement of Behcet’s disease: a pilot double-blind control study

مولف: Mastaneh MOHAMMADI, 1 Farhad SHAHRAM, 1 Hormoz SHAMS, 1, 2 Massoomeh AKHLAGHI, 1 Farimah ASHOFTEH1 and Fereydoun DAVATCHI1

خلاصه: Aim: To evaluate the efficacy of intravenous high-dose pulses of methylprednisolone (IVPM) for treatment of ocular involvement in Behcet’s disease (BD). Method: In a double-blind control study, we randomized BD patients with posterior uveitis (PU) and/or retinal vasculitis (RV) into two groups. They received either IVPM (1000 mg methylprednisolone) or placebo for 3 consecutive days. Both groups received combination therapy with IV cyclophosphamide, azathioprine and prednisolone for 6 months. Visual acuity (VA), Disease Activity Index ... سال انتشار: 2017
 

Clinical features of Behcet ’ s disease in patients without oral aphthosis

Authers: Seyedeh Tahereh Faezi 1 , Pedram Paragomi 1 , Farhad Shahram 1 , Hormoz Shams 2 , Cheida Shams-Davatchi 3 , Zahra Ghodsi 3 , Abdolhadi Nadji 1 , Maassoumeh Akhlaghi 1 , and Fereydoun Davatchi 1

Abstract: In current study we evaluated clinical features of Behcet ’ s Disease (BD) in patients without oral aphthosis (NOA cases). Methods. In a cohort of BD, patients registered during a period of 36 years were collected. We determined clinical features of BD NOA cases and compared them with patients with oral aphthosis (OA cases). The comparison was performed by chi square and Fischer ’ s exact test. Results. Among 6821 BD patients, 175 patients (2.56%) ... سال انتشار: 2013
 

Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet’s disease retinal vasculitis: report of three patients

Authers: Fereydoun DAVATCHI, 1 Behrooz NIKBIN, 2 Hormoz SHAMS, 1 Bahar SADEGHI ABDOLLAHI, 1 Mandana MOHYEDDIN2 and Farhad SHAHRAM1

Abstract: Retinal vasculitis (RV) is the most aggressive lesion of ocular manifestations of Behcet’s disease, seen in 32.1% of patients. Although visual acuity (VA) improves with early and aggressive treatment, in the long run it is seen in only 48% of patients. Mesenchymal stem cell (MSC) transplantation (MSCT) can theoretically reverse the RV process. Patients and Methods: Three patients with advanced RV and very low VA were selected. Eyes selected for MSCT were legally blind (no ... سال انتشار: 2013